Table 1.
DC development, subsets and lineage-specific markers.
| Dendritic cells | Location | Human | Mice | ||
|---|---|---|---|---|---|
| Alternative Subset Name | Surface Markers | Alternative Subset Name | Surface Markers | ||
| Conventional DCs (cDCs) | Myeloid (Blood) | CD1c/BDCA-1+ | CD1c+, CD11c+++, CX3CR1+, CD172a+, CD64+ | CD11b+/CD103+ | CD103 integrin marker (aE b7), IRF8 |
| CD141+/BDCA-3+ | CD141+, CD11c+++, CLE9A+, XCR1+, BDCA-3+ | CD8+ | CD8α+, NECL2 (CADM1), CLE9A, BATF3, XCR1 | ||
| Non-lymphoid tissue (NLT) skin, liver, lung and intestine |
CD1c+ | CD11c++, CD1c+, CD172a+, CD11b+, CD206+, CD64+, Lower expression of FLT3 and CLEC9A and intermediatelevels of M-CSFR and CX3CR1, compared with CD141+ | CD11b+/CD103+ | CD11c++, CD11b++, CD103 integrin marker (aEb7), CD24++, CD209a+, IRF8 | |
| CD141+/CLEC9A+ | CD11c+, XCR1+, TLR3, CLEC9+, CD141+, CADM1, CCR7 | CD11b+/CD103 | CD11c++, CD103 integrin marker (aEb7), CD24+, XCR1+, IRF8 | ||
| CD141+ | CD11c++, CD141+, CX3CR1+, CD1c+, CD172a+, CD11b+, CD206+, CD14+ | ||||
| Lymphoid tissue (LT) | CD141+ | CD141+, CD11c++, CLEC9A+, XCR1+ | CD11b+ | CD4, Endothelial cell-selective adhesion molecule (ESAM), EB12 | |
| CD1c+ | CD1c+, CD11c+++ | CD8a- | CD11c++, CD11b++, CD4, SIRPa+, DCAL2, Clec 12a, CD209a+, F4/80+ | ||
| CD11c+ | CD123 (IL-3R), CD303 (BDCA-2), CD304 (BDCA-4 or Neuropilin-1) | CD8a+ | CD8++, CD11c++, CD11b++, CD103+, CD86+, CD24+, Xcr1+, TLR3, T. gondii sensor, TLR11 | ||
| Plasmacytoid (pDcs) | Blood and lymph node (LN) | CD11c+ | CD123 (IL-3R), CD303 (BDCA-2), CD304 (BDCA-4 or Neuropilin-1) | Pre-conventional DCs (pre-cDCs) | PDCA-1 |
| Langerhans cells (LCs) | Epidermal | CD1a | Langerin (CD207+), CD11c+, BDCA1+, CD172a+, CD11b+, CD1a++, E-cadherin+, CD326+, XCR1, CSF1R | LCs | CD11c+, Langerin (CD207+), XCR1+ |
| DCs | Dermal | CD1a+ CD14− | CD1a+ CD14− | CD103+CD207+ | IRF8, ID2, BATF3, CLEC9A, XCR1 |
| CD103+CD207+ | |||||
| CD14+ | M-CSFR, CX3CR1, CD209 (DC-SIGN) | CD207− CD11b+ | |||
| CD207−, CD11b−, CD103− | |||||